Cure My Disease

Don't miss your cure!

 Log in / Sign up

Common diabetes drug may slow rare abdominal cancer

NCT ID NCT07693452

Recruiting now Disease control Sponsor: University of California, Irvine Source: ClinicalTrials.gov ↗

First seen Jul 09, 2026 · Last updated Jul 14, 2026 · Updated 3 times

Summary

This trial tests whether metformin, a common diabetes medication, can help people with pseudomyxoma peritonei, a rare cancer that spreads in the abdomen. The study includes adults whose cancer has returned or cannot be surgically removed. Researchers will measure how many participants can take metformin for six months and whether it slows tumor growth.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
metformin
What this could lead to
If it works, this could point toward a new, well-tolerated treatment option for a rare abdominal cancer that is hard to treat.
What could go wrong
This is a very small pilot study with only 15 people, so results may not apply broadly. Metformin may cause side effects like stomach upset, and it is not a cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for APPENDICEAL MUCINOUS NEOPLASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mucinous adenocarcinoma of the appendix pseudomyxoma peritonei

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

APPENDICEAL MUCINOUS NEOPLASM PSEUDOMYXOMA PERITONEI

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

Locations

  • Chao Family Comprehensive Cancer Center, University of California, Irvine

    RECRUITING

    Orange, California, 92868, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.